23.04.2024 22:17:42 - dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
plc (http://www.centessa.com/) (Nasdaq: CNTA), a clinical-stage pharmaceutical
company that aims to discover and develop medicines that are transformational
for patients, today announced that it has commenced an underwritten public
offering of $100 million of American Depositary Shares ("ADSs"), each
representing one ordinary share. All of the ADSs are being offered by Centessa.
In addition, Centessa intends to grant the underwriters a 30-day option to
purchase up to an additional $15 million of ADSs offered in the public offering.
The proposed offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
Goldman Sachs and Leerink Partners are acting as lead joint book-running
managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO
Capital Markets are also acting as joint book-running managers for the proposed
offering.
The ADSs are being offered pursuant to a registration statement on Form S-3 that
was previously filed with, and subsequently declared effective on July 12, 2022
by, the Securities and Exchange Commission ("SEC"). A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be filed
with the SEC and will be available on the SEC's website located
at http://www.sec.gov. Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering, when available, may be
obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West
Street, New York, New York 10282, telephone: 1-866-471-2526, email: prospectus-
ny@ny.email.gs.com; and Leerink Partners LLC, Syndicate Department, 53 State
Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext.
6105, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that
aims to discover and develop transformational medicines for patients. Our most
advanced programs include a hemophilia program, an orexin agonist program for
the treatment of narcolepsy and other sleep-wake disorders and an immuno-
oncology program focused on our LockBody® technology platform. We operate with
the conviction that each of our programs has the potential to change the current
treatment paradigm and establish a new standard of care. For more information,
visit www.centessa.com (http://centessa.com/), which does not form part of this
release.
Forward Looking Statements
This press release contains forward-looking statements. Any such statements in
this press release that are not statements of historical fact may be deemed to
be forward-looking statements, including those relating to Centessa's
expectations regarding the completion, timing and size of the public offering
and its expectations with respect to granting the underwriters a 30-day option
to purchase additional shares. Any forward-looking statements in this press
release are based on our current expectations, estimates and projections only as
of the date of this release and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and adversely
from those set forth in or implied by such forward-looking statements. These
risks and uncertainties related to completion of the proposed public offering on
the anticipated terms, or at all, include, but are not limited to, market
conditions and the satisfaction of customary closing conditions related to the
proposed public offering. Risks concerning our programs and operations are
described in additional detail in our Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q, and our other reports, which are on file with the U.S.
Securities and Exchange Commission (SEC). We explicitly disclaim any obligation
to update any forward-looking statements except to the extent required by law.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
Â